Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Takes Action Against Propoxyphene But Keeps It On The Market

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA denies Public Citizen's request for withdrawal, instead mandating new studies to assess propoxyphene's link to overdoses and requiring a boxed warning and MedGuide.
Advertisement

Related Content

Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study
Propoxyphene Marketing Halted By FDAAA-Required QT Safety Study
A Lack Of Data Keeps Propoxyphene On The Market ... For Now At Least
A Lack Of Data Keeps Propoxyphene On The Market ... For Now At Least
Public Citizen Takes On Propoxyphene Again, This Time Comes Out On Top
Public Citizen Takes On Propoxyphene Again, This Time Comes Out On Top

Topics

Advertisement
UsernamePublicRestriction

Register

PS069796

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel